The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Drugs for Allosteric Sites on Receptors
Open accessAbstract
The presence of druggable, topographically distinct allosteric sites on a wide range of receptor families has offered new paradigms for small molecules to modulate receptor function. Moreover, ligands that target allosteric sites offer significant advantages over the corresponding orthosteric ligands in terms of selectivity, including subtype selectivity within receptor families, and can also impart improved physicochemical properties. However, allosteric ligands are not a panacea. Many chemical issues (e.g., flat structure-activity relationships) and pharmacological issues (e.g., ligand-biased signaling) that are allosteric centric have emerged. Notably, the fact that allosteric sites are less evolutionarily conserved leads to improved selectivity; however, this can also lead to species differences that can hinder safety assessment. Many allosteric ligands possess molecular switches, wherein a small structural change (chemical or metabolic) can modulate the mode of pharmacology or receptor subtype selectivity. As the field has matured, as described here, key principles and strategies have emerged for the design of ligands/drugs for allosteric sites.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
On the nature of allosteric transitions: A plausible model
Monod, J., Wyman, J., & Changeux, J.-P. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80285-6 · Cited by 8,825
Protein kinases — the major drug targets of the twenty-first century?
Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,186
Copeland, R. A. (2005) · PubMed · Cited by 1,092
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2760 · Cited by 1,063
Self-citationOperational models of pharmacological agonism
Black, J. W., & Leff, P. (1983) · Proceedings of the Royal Society of London. Series B. Biological Sciences · doi:10.1098/rspb.1983.0093 · Cited by 951
G Protein-Coupled Receptor Allosterism and Complexing
Christopoulos, A., & Kenakin, T. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.323 · Cited by 931
Hirai, H., Sootome, H., Nakatsuru, Y., Miyama, K., Taguchi, S., Tsujioka, K., Ueno, Y., Hatch, H., Majumder, P. K., Pan, B.-S., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1012 · Cited by 860
Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis
Copeland, R. A. (2000) · Wiley eBooks · doi:10.1002/0471220639 · Cited by 726
A new benzodiazepine pharmacology
Möhler, H., Fritschy, J. M., & Rudolph, U. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.1.2 · Cited by 716
The Organic Chemistry of Drug Design and Drug Action
(1992) · Elsevier eBooks · doi:10.1016/c2009-0-22221-5 · Cited by 712
Research works printed but not linked: 16
- Digby GJ, 2010, Curr. Opin. Drug Discov. Dev., 13, 577
- Meanwell NA, 2007, Curr. Opin. Investig. Drugs, 8, 669
- Kim D, 2005, Curr. Opin. Investig. Drugs, 6, 1250
- Carey FA, 2008, Advanced Organic Chemistry, Part A: Structure and Mechanisms
- 10.1159/000118141 · doi:10.1159/000118141
- 10.1016/j.bmcl.2010.12.110 · doi:10.1016/j.bmcl.2010.12.110
- 10.1021/cn300103e · doi:10.1021/cn300103e
- 10.1021/jm010946z · doi:10.1021/jm010946z
- 10.1016/j.bmcl.2011.04.101 · doi:10.1016/j.bmcl.2011.04.101
- 10.1124/mol.112.078808 · doi:10.1124/mol.112.078808
- Amoah-Apraku B, 1993, J. Pharmacol. Exp. Ther., 266, 611, 10.1016/S0022-3565(25)38385-0 · doi:10.1016/s0022-3565(25)38385-0
- 10.1016/0167-4889(94)00204-R · doi:10.1016/0167-4889(94)00204-r
- Kollias-Baker CA, 1997, J. Pharmacol. Exp. Ther., 281, 761, 10.1016/S0022-3565(24)36657-1 · doi:10.1016/s0022-3565(24)36657-1
- 10.1124/mol.64.6.1557 · doi:10.1124/mol.64.6.1557
- Roszkowski AP, 1961, J. Pharmacol. Exp. Ther., 132, 156, 10.1016/S0022-3565(25)26023-2 · doi:10.1016/s0022-3565(25)26023-2
- 10.1124/mol.107.037630 · doi:10.1124/mol.107.037630
Cited by
Inferring the molecular and phenotypic impact of amino acid variants with MutPred2
Pejaver, V., Urresti, J., Lugo-Martinez, J., Pagel, K. A., Lin, G. N., Nam, H.-J., Mort, M., Cooper, D. N., Sebat, J., Iakoucheva, L. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19669-x · Cited by 923
Srinivasarao, M., & Low, P. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00013 · Cited by 605
Controlling Allosteric Networks in Proteins
Dokholyan, N. V. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00544 · Cited by 260
Conn, P. J., Lindsley, C. W., Meiler, J., & Niswender, C. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4308 · Cited by 260
Self-citationβ-amyloid redirects norepinephrine signaling to activate the pathogenic GSK3β/tau cascade
Zhang, F., Gannon, M., Chen, Y., Yan, S., Zhang, S., Feng, W., Tao, J., Sha, B., Liu, Z., Saito, T., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay6931 · Cited by 133
Metadata
- Authors
- Wenthur, C. J., Gentry, P. R., Mathews, T. P., & Lindsley, C. W.
- Venue
- Annual Review of Pharmacology and Toxicology
- Publisher
- Annual Reviews
- Published
- 2014-01-06
- Volume
- 54
- Issue
- 1
- Pages
- 165-184
- ISSN
- 0362-1642 (ISSN-L)
- 1545-4304
- OpenAlex
- W2154249927
- Cited by
- 273
- References
- 86
- FWCI
- 0.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drugs for Allosteric Sites on Receptors. https://app.cochat.ai/papers/10.1146/annurev-pharmtox-010611-134525
- The paper
- Wenthur, C. J., Gentry, P. R., Mathews, T. P., & Lindsley, C. W. (2014). Drugs for Allosteric Sites on Receptors. Annual Review of Pharmacology and Toxicology. https://doi.org/10.1146/annurev-pharmtox-010611-134525
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.